Table 4.

Cost-Effectiveness Analysis for Matched Analytic Population Subgroups

	Δ CABG - PCI	Life Years or QALY Gained with CABG	ICER	% CABG Dominated	% CABG Dominant	% <$30,000 /LYG	% < $50,000 /LYG	% <$100,000 /LYG
Diabetes	$14,069	0.5525	$25,467	0	0	100.0	100.0	100.0
No diabetes	$11,075	0.3051	$36,298	0	0	0	100.0	100.0
Age >75 yr	$12,407	0.3863	$32,118	0	0	1.0	100.0	100.0
Age ≤75 yr	$11,806	0.4046	$29,182	0	0	70.0	100.0	100.0
White	$12,021	0.3999	$30,060	0	0	46.0	100.0	100.0
Non-white	$13,377	0.3511	$38,102	0	0	0	95.0	100.0
Male	$11,496	0.3922	$29,309	0	0	72.0	100.0	100.0
Female	$13,432	0.3987	$33,693	0	0	0	100.0	100.0
No angina	$14,914	0.5842	$25,527	0	0	99.0	100.0	100.0
Stable angina	$9,600	0.2262	$42,443	0	0	0	94.0	100.0
Unstable angina	$12,439	0.4066	$30,484	0	0	37.0	100.0	100.0
2-vessel disease	$10, 943	0.2589	$42,269	0	0	0	95.0	100.0
≥3-vessel disease	$12,883	0.4758	$27,080	0	0	99.0	100.0	100.0
HF	$20,213	0.8216	$24,602	0	0	100.0	100.0	100.0
No HF	$11,090	0.3376	$32,848	0	0	0	100.0	100.0

HF = heart failure; other abbreviations as in Tables 1, 2, and 4.